HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Robert Stroud Peter Damiani Mikhail Vaynblat Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Smith, A. I. Articles by Vaynblat, M. Search for Related Content PubMed Articles by Smith, A. I. Articles by Vaynblat, M. Related Collections Cardiac - other Extracorporeal circulation Valve disease

Case reports

Use of Argatroban for anticoagulation during cardiopulmonary bypass in a patient with heparin allergy

Division of Cardiothoracic Surgery, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY 11219, USA

Received 22 January 2008; received in revised form 20 May 2008; accepted 23 July 2008.

^_* Corresponding author. Tel.: +1 718 283 7686; fax: +1 718 283 7392. (Email: mishavayn{at}aol.com).

The use of Argatroban for treatment of heparin-induced thrombocytopenia (HIT) and for percutaneous coronary intervention in patients with HIT is well described and FDA approved. The use of Argatroban for cardiopulmonary bypass remains off label and the subject of a few case reports. We report the case of a patient with a heparin allergy requiring cardiopulmonary bypass (CPB) for mitral valve replacement. Argatroban was successfully used as anticoagulation for CPB.

Key Words: CPB • Anticoagulation • Mitral valve replacement